Centanafadine May Offer Second-Line Option for Patients With ADHD If Stimulants Fail
Pharmacy Times
Centanafadine, a newly approved triple reuptake inhibitor for ADHD, may serve as a second-line treatment option for patients who do not respond to stimulants. While its overall symptom reduction effect size is modest compared to stimulants, it shows more promise in improving executive functioning. Safety data from clinical trials indicates a favorable profile, though further research may be needed to fully establish its role in ADHD management.
All articles from 18 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.